Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 2.5mg dose of Mounjaro is taken for four weeks only. It is a tolerability dose, not a therapeutic one — its job is to let your body adjust to tirzepatide before your prescriber steps you up to 5mg. Most people take it for exactly one pen (four doses), then move on. These are prescription-only medicines; a GPhC-registered prescriber decides the timing of every step, based on how you're responding and tolerating the treatment. Some people do stay at 2.5mg longer than four weeks — but that is a clinical call, not a personal one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is whether patients should extend the 2.5mg pen because they are not losing weight quickly enough. The short answer is no. The 2.5mg dose was never designed to produce meaningful weight loss. Its role, as set out in the Mounjaro Summary of Product Characteristics on the eMC, is to give your gastrointestinal system time to adjust to tirzepatide before the dose climbs to a level where the medicine starts doing its primary job. Nausea, indigestion and loose stools are common at the start of any GLP-1 or dual-agonist treatment; starting low reduces how sharply those effects hit.
Think of the first pen as four weeks of calibration. You are not losing the time, you are making the rest of the titration schedule more manageable. The weight loss story begins at 5mg and continues as your prescriber guides the dose upward over subsequent months. Expecting 2.5mg to deliver the results you have read about in clinical trials is the wrong frame entirely. Our Mounjaro overview covers what the full treatment course looks like from start to finish.
For most people, the answer to how long they take 2.5mg is straightforward: one pen, four injections, four weeks, then 5mg. The licensed titration schedule moves in four-week steps throughout, so the rhythm you establish at the start carries through the whole programme.
There are circumstances where a prescriber may recommend staying at 2.5mg for longer. If side effects at the starting dose are significant (persistent nausea that is interfering with daily life, for instance) it may be clinically sensible to hold before increasing. This is not a common situation, but it happens. What does not change is the principle: the timing is a clinical judgement, not something to adjust based on how quickly the scales are moving. Correct injection technique also plays a part in how well the starting dose is tolerated; small details matter.
If you are thinking about what comes next, how long 5mg takes to produce noticeable effects is a natural follow-on question, and the answer is more nuanced than most people expect.
Strictly speaking, it is not your decision to make alone. Mounjaro is a prescription-only medicine, and the prescriber who approved your treatment is responsible for reviewing each step. At nume, a GPhC-registered Independent Prescriber reviews your case before every repeat order. That means by the time your first pen is finished, a clinician has already looked at your progress, any side effects you have reported, and whether moving to 5mg is the right call. You do not need to self-assess and guess.
The factors a prescriber weighs are tolerability first, then clinical progress. Side effects that are still pronounced, any new health information, or a change in the medicines you take alongside Mounjaro all feed into that review. For context on what the dose progression looks like across the full schedule, the dose-per-click guide explains how each pen delivers its weekly injections. And if you have ever wondered whether there is a clinically optimal point to stay at during titration, the question behind the so-called golden dose is worth reading before drawing your own conclusions.
The NHS tirzepatide page at nhs.uk/medicines/tirzepatide also sets out the licensed titration schedule in plain language, which is useful reading before your first consultation or repeat review.
Life interrupts. If you miss a dose during the 2.5mg phase, the approach is the same as at any other point in treatment: what to do after a missed Mounjaro dose depends on how much time has passed, and the answer is not always what people assume. The short version is that timing rules apply, but the detail is in your Patient Information Leaflet and with your prescriber, not in a general article.
Stopping at 2.5mg entirely is almost always the wrong move. You will not have given tirzepatide a genuine chance at the dose range where it works. If you are struggling with side effects, talk to the prescribing team before stopping. Our aftercare team is available seven days a week for exactly this kind of conversation, that is part of what the treatment includes, with no separate charge. If you are still weighing up whether tirzepatide is right for you, checking your eligibility through a free consultation is the place to start. There is no obligation to proceed, and it gives you a clinical picture before you commit.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.